依普利酮医保报销后价格多少？

The clinical trial method selected a total of 116 patients with mild and moderate hypertension from February 2010 to February 2012, and randomly divided them into group A and group B, 58 patients each. Group A was treated with eplerenone (Inspra), and group B was treated with losartan potassium tablets. Results After treatment, the total effective rate of group A was 91.38%, which was significantly higher than that of the control group, which was 89.66%. At the same time, the systolic blood pressure and diastolic blood pressure of patients in both groups were significantly lower than before treatment; however, there was no significant difference in the systolic blood pressure and diastolic blood pressure between the two groups. At the same time, the monthly decreases in systolic blood pressure and diastolic blood pressure of patients in each group were compared, and the differences were not statistically significant. Patients in both groups experienced serious adverse reactions. There was no significant difference in the incidence of adverse reactions between the two groups. Conclusion: Losartan and eplerenone can both effectively improve patients' blood pressure in the treatment of moderate and mild hypertension without serious adverse reactions, which has clinical application value.

Eplerenone (Inspra) has a remarkable effect in treating hypertension. In addition to treating hypertension, eplerenone (Inspra) is also approved to treat congestive heart failure after acute myocardial infarction. Eplerenone (Inspra) is also effective in treating congestive heart failure after acute myocardial infarction.

So has eplerenone (Inspra) been launched in China and has it been covered by medical insurance? What is the price of eplerenone (Inspra) after medical insurance?

At present, eplerenone (Inspra) has not been launched in China, so eplerenone (Inspra) has not been included in medical insurance. The price after medical insurance reimbursement cannot be known. Eplerenone is currently on the market in India. The eplerenone on the market in India is produced by Lupine Pharmaceuticals of India. The specification of eplerenone is 50mg*100 tablets, and the price is equivalent to RMB 500. For the specific price of eplerenone (Inspra), please consult the medical companion and travel service.